• To observe the clinical outcome of unresectable, stage III NSCLC [ Time Frame: Date of enrollment in the study until end of follow-up or death if this occurs before, assessed approximately up to 36 months ]
  Overall survival measured from the date of treatment initiation in the study to the date of death due to any cause; Progression-free Survival (PFS) measured from the date of treatment initiation in the study, until physician-reported progression or death due to any cause, whichever occurs first.
• To observe molecular testing patterns of stage III NSCLC [ Time Frame: Date of enrollment in the study until end of follow-up or death if this occurs before, assessed approximately up to 36 months ]
  Molecular testing patterns including: Molecular testing rate defined as the number of patients who received molecular testing divided by total patient's number; Molecular testing details including sample type, test type; Molecular testing results.
• To estimate parameters associated with radiation pneumonitis [ Time Frame: Date of enrollment in the study until end of follow-up or death if this occurs before, assessed approximately up to 36 months ]
  Assessment of radiation pneumonitis observed with radiotherapy among patients with unresectable, stage III NSCLC
• To observe adjuvant treatment patterns of resectable, stage III NSCLC [ Time Frame: Date of enrollment in the study until end of follow-up or death if this occurs before, assessed approximately up to 36 months ]
  Adjuvant treatment received post surgery including chemotherapy, targeted therapy and radiotherapy.

• Cohort 1
  Cohort 1, including patients without surgical resection, will be defined as unresectable stage III NSCLC
• Cohort 2
  Cohort 2,including patients with surgical resection, will be defined as resectable stage III NSCLC

Inclusion Criteria:

• Male or female aged 18 years or older.
• Provision of informed consent prior to any study specific procedures.
• Histologically or cytologically confirmed locally advanced, stage III NSCLC (according to version 8 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology; IASLC Staging Manual in Thoracic Oncology).

Exclusion Criteria:

• Enrolment in studies that prohibit any participation in this observational study.

  • Patients may be concurrently enrolled in unblinded clinical trials, but not blinded clinical trials in which the treatment being administered is unknown.
• Prior surgery, radiotherapy or systemic therapy for NSCLC, including chemotherapy, targeted therapy, anti-angiogenesis, etc.